IDXX — IDEXX Laboratories, Inc.

IDEXX Laboratories Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: Increased 14% (12% organic growth), driven by a 10% organic growth in CAG Diagnostics recurring revenues.
• Earnings Per Share (EPS): $3.08, up 17% year-over-year on a comparable basis.
• Full-Year Revenue: Achieved 10% organic growth, with CAG Diagnostics recurring revenues up 8%.
• Operating Margins: Reached 31.6% for the full year, a 90 basis point increase on a comparable basis.
• Free Cash Flow: $1.1 billion for 2025, representing 100% of net income.
• Share Repurchases: $1.2 billion allocated for repurchasing 2.4 million shares.

2. Strategic Updates and Business Highlights

• Record Instrument Placements: Over 6,500 premium instruments placed in Q4, including 1,900 IDEXX InVue DX placements, contributing to a 69% year-over-year expansion in CAG Diagnostic instrument revenues.
• Innovation Focus: Successful launches of new platforms such as InVueDx and CancerDx, enhancing diagnostic capabilities and driving customer engagement.
• International Growth: Strong performance in international markets, with CAG Diagnostics recurring revenue growth of 12% in Q4.
• Software Solutions: Continued growth in cloud-based software, with Velo user base expanding by over 40%, enhancing clinic engagement and diagnostic usage.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $4.632 billion and $4.72 billion, representing a 7.6% to 9.6% increase on a reported basis.
• CAG Diagnostics Recurring Revenue Growth: Projected to grow 8% to 10% organically in 2026.
• EPS Outlook for 2026: Estimated between $14.29 and $14.80 per share, reflecting a 10% to 14% increase on a comparable basis.
• Q1 2026 Guidance: Anticipated organic revenue growth of 9% to 11%, with CAG Diagnostic recurring revenue growth of 8.5% to 10.5%.

4. Bad News, Challenges, or Points of Concern

• Clinical Visit Declines: U.S. same-store clinical visit growth declined by approximately 1.7% in Q4 and 1.9% for the full year 2025, with wellness visits particularly pressured.
• Price Realization: Expected net price realization for 2026 is approximately 4%, slightly lower than 2025, indicating potential pricing pressures.
• Macro Economic Pressures: Ongoing economic challenges affecting customer spending, particularly in lower-income demographics, may continue to impact wellness visits.

5. Notable Q&A Insights

• Wellness vs. Non-Wellness Visits: Management noted that non-wellness visits are more resilient to macro pressures, while wellness visits are experiencing declines due to economic factors.
• Innovation Contribution: While InVue and CancerDx are expected to drive future growth, their direct revenue contributions in 2025 were modest. The focus remains on leveraging these innovations to enhance overall diagnostic utilization.
• Pricing Dynamics: Conversations with veterinary clinics indicate a recognition of the need for balanced pricing strategies amidst economic pressures, with some moderation in price increases observed.

This summary encapsulates the key financial metrics, strategic initiatives, forward-looking guidance, and challenges faced by IDEXX Laboratories, providing a balanced view of the company's performance and outlook.